Targets › HTR6
1 program from 1 company in 1 trial: 1 Phase 3; Neurology; next expected readout Dec 2026.
G protein-coupled receptor for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone and a mitogen. Also has a high affinity for tricyclic psychotropic drugs (By similarity). (UniProt, P50406)
Open in Phaseline: the race on HTR6, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Suven Life Sciences | Masupirdine (SUVN-502) Serotonin 6 (5-HT6) receptor antagonist | HTR6 | Phase 3 | Agitation | Dec 2026 |
Agitation (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.